P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS

• C. Harrison,
• R. K. Rampal,
• V. Gupta,
• S. Verstovsek,
• M. Talpaz,
• J.-J. Kiladjian,
• R. Mesa,
• A. Kuykendall,
• A. Vannucchi,
• F. Palandri,
• S. Grosicki,
• T. Devos,
• E. Jourdan,
• M. J. Wondergem,
• H. K. Al-Ali,
• V. Buxhofer-Ausch,
• A. Alvarez-Larrán,
• S. Akhani,
• R. Muñoz-Carerras,
• Y. Sheykin,
• G. Colak,
• M. Harris,
• J. Mascarenhas

Affiliations

C. Harrison

1 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

R. K. Rampal

2 Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America

V. Gupta

3 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

S. Verstovsek

4 Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX

M. Talpaz

5 University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, United States of America

J.-J. Kiladjian

6 Hôpital Saint-Louis, Université de Paris, Paris, France

R. Mesa

7 Mays Cancer Center at UT Health San Antonio MD Anderson Cencer Center, San Antonio, TX

A. Kuykendall

8 Mofitt Cancer Center, Tampa, FL, United States of America

A. Vannucchi

9 Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence

F. Palandri

10 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy

S. Grosicki

11 Medical University of Silesia in Katowice, Katowice, Poland

T. Devos

12 University Hospitals Leuven and Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium

E. Jourdan

13 C.H.U, Nîmes, France

M. J. Wondergem

14 Amsterdam University Medical Centers, Amsterdam, Netherlands

H. K. Al-Ali

15 University Hospital Halle, Halle, Germany

V. Buxhofer-Ausch

16 KRANKENHAUS DER ELISABETHINEN Linz GmbH, Linz, Austria

A. Alvarez-Larrán

17 Hospital Clínic Barcelona, Barcelona, Spain

S. Akhani

18 MorphoSys AG, Planegg, Germany

R. Muñoz-Carerras

19 Constellation Pharmaceuticals a MorphoSys Company, Boston, MA

Y. Sheykin

19 Constellation Pharmaceuticals a MorphoSys Company, Boston, MA

G. Colak

19 Constellation Pharmaceuticals a MorphoSys Company, Boston, MA

M. Harris

19 Constellation Pharmaceuticals a MorphoSys Company, Boston, MA

J. Mascarenhas

20 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America